Boehringer Ingelgeim and PhoreMost have reached another milestone payment in their multi-project target discovery collaboration.
This followed the identification and validation of novel targets for diseases affecting retinal health.
Utilising SITESEEKER to discover novel disease pathways
PhoreMost and Boehringer Ingelheim entered the multi-project collaboration back in January 2020.
In this second project, PhoreMost is deploying its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, towards novel disease-relevant pathways focusing on retinal health — a key research area of Boehringer Ingelheim.
The first milestone payment was triggered in January 2023, following successful target identification and validation in a separate project under the same collaboration.
CEO of PhoreMost Dr Neil Torbett said: “Achieving this second milestone, in our collaboration with Boehringer Ingelheim demonstrates the power of the SITESEEKER platform and the partnership moving forward. We remain very excited about the potential of our technology to identify novel drug targets across a range of therapeutic areas, and to contribute to the development of therapeutics for patients in need.”
As with targets previously identified under the collaboration, Boehringer Ingelheim will continue the development of potential new therapies against these targets.,
The company anticipates this will lead to potential further success-based pre-clinical, clinical and commercial milestone payments.